Atrium Therapeutics annual ebitda
2023
2024
2025
Atrium Therapeutics EBITDA Growth & History (RNA)
Atrium Therapeutics's calculated EBITDA was −$76.5M for fiscal 2025.
View full Atrium Therapeutics company overviewAtrium Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$76.5M | −$63.4M | — |
| 2024 | 2024-12-31 | −$13.0M | −$6.8M | — |
| 2023 | 2023-12-31 | −$6.2M | — | — |
Atrium Therapeutics quarterly ebitda
Q4.24
Q1.26
Q2.26
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 · Jun 30 | 2026-06-30 | −$22.3M | −$9.5M | — |
| Q1 2026 · Mar 31 | 2026-03-31 | −$17.1M | −$9.7M | — |
| Q4 2025 | 2025-12-31 | −$47.9M | −$3.7M | — |
| Q3 2025 | 2025-09-30 | −$8.4M | — | — |
| Q2 2026 · Jun 30 | 2025-06-30 | −$12.8M | — | — |
| Q1 2026 · Mar 31 | 2025-03-31 | −$7.4M | — | — |
| Q4 2024 | 2024-12-31 | −$44.2M | — | — |
Atrium Therapeutics ebitda trends
Between the periods ended 2023-12-31 and 2025-12-31, Atrium Therapeutics's ebitda decreased from −$6.2M to −$76.5M, a change of −$70.2M. The latest reported quarter, Q2 2026 · Jun 30, shows −$22.3M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Atrium Therapeutics source filings ↗